Tyra Biosciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$148.6MTTM through 30 Jun 2026
Free Cash Flow -$109.9MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-33.8%ROE
-31.8%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio20.49x
Net Debt-$375.9Mnet cash position
Cash & Equivalents$73.8M
Quality Metrics
Altman Z-Score33.54
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%
Multi-Year Trend
Diluted EPS-$2.39TTMFY2025: $-2.01
Dividend
No dividend
Capital Allocation
R&D Spend$126.3M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.